advertisement
Abstract #19772 Published in IGR 9-4
Comparative evaluation of bimatoprost monotherapy in primary chronic angle closure and primary open angle glaucoma eyes: A three-year study
Gupta V; Srinivasan G; Sharma A; Kapoor KS; Sihota RJournal of Ocular Pharmacology and Therapeutics 2007; 23: 351-358
AIMS: The aim of this study was to compare the long-term efficacy of bimatoprost 0.03% monotherapy in primary open angle glaucoma (POAG) versus primary chronic angle closure glaucoma (PCACG) eyes. METHODS: A total of 55 consecutive primary adult glaucoma patients on bimatoprost monotherapy were prospectively evaluated in this three-year, open-labeled, uncontrolled study. The primary outcome was the evaluation of a difference in the response to therapy of POAG eyes, as compared to PCACG eyes over a follow-up of three years. RESULTS: In the POAG group, the mean intraocular pressure (IOP) at the 36-month follow-up was found to be increased by 2.10 (± 3.90) mmHg (confidence interval [CI], 0.975-4.185), compared to the mean IOP at one month (P = 0.047). In the PCACG group, the mean IOP at the 36-month follow-up was increased by 3.66) (± 3.34) mmHg (CI, 6.241-1.092), compared to the mean IOP at one month (P = 0.011). This upward drift in IOP was higher in the PCACG group, compared to the POAG group, but this was not statistically significant (P = 0.54). Patients with POAG and PCACG showed a 50% and 40% chance of having an IOP of <18 mmHg with bimatoprost monotherapy (P = 0.23), respectively, at the three-year follow-up. CONCLUSIONS: This study showed that bimatoprost 0.03% monotherapy significantly lowers IOP in both POAG and PCACG eyes over a period of three years, though its efficacy appeared to decrease over time, to a similar extent, in both groups.
Dr. V. Gupta, Department of Ophthalmology, Glaucoma Research Facility & Clinical Services, Dr Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India. Gupta_v20032000@yahoo.com
Classification:
11.4 Prostaglandins (Part of: 11 Medical treatment)
13.2.1 IOP (Part of: 13 Therapeutic prognosis and outcome > 13.2 Outcome)